GoalVest Advisory LLC Sells 250 Shares of Novo Nordisk A/S (NYSE:NVO)

GoalVest Advisory LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 12.0% during the first quarter, HoldingsChannel reports. The firm owned 1,837 shares of the company’s stock after selling 250 shares during the period. GoalVest Advisory LLC’s holdings in Novo Nordisk A/S were worth $128,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. GAMMA Investing LLC grew its holdings in shares of Novo Nordisk A/S by 7,508.7% in the first quarter. GAMMA Investing LLC now owns 657,319 shares of the company’s stock worth $45,644,000 after purchasing an additional 648,680 shares during the last quarter. AdvisorNet Financial Inc grew its holdings in shares of Novo Nordisk A/S by 34.0% in the first quarter. AdvisorNet Financial Inc now owns 3,741 shares of the company’s stock worth $260,000 after purchasing an additional 950 shares during the last quarter. Webster Bank N. A. grew its holdings in shares of Novo Nordisk A/S by 708.8% in the first quarter. Webster Bank N. A. now owns 39,637 shares of the company’s stock worth $2,752,000 after purchasing an additional 34,736 shares during the last quarter. Sage Capital Advisors llc bought a new position in shares of Novo Nordisk A/S in the first quarter worth about $3,210,000. Finally, Moody National Bank Trust Division bought a new position in shares of Novo Nordisk A/S in the first quarter worth about $224,000. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on NVO shares. Dbs Bank cut shares of Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an “underperform” rating on the stock. Guggenheim cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. BMO Capital Markets reiterated a “market perform” rating and set a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Finally, Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average price target of $135.00.

Novo Nordisk A/S Stock Up 1.3%

NYSE:NVO opened at $69.46 on Friday. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The stock has a market capitalization of $311.71 billion, a P/E ratio of 21.11, a P/E/G ratio of 0.90 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company’s 50-day simple moving average is $65.63 and its 200-day simple moving average is $82.01.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The business had revenue of $11.87 billion for the quarter. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.